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HYMENOPTERA VENOM ALLERGY IN HUMANS
Abstract: Hymenoptera venom allergy in humans
Reactions to Hymenoptera stings may appear as local or systemic responses. According to European 
data, the incidence of systemic reactions to Hymenoptera stings in the general population is 0.3–7.5%, 
with the value being 0.3-0.8% in children and 14–43% in beekeepers. The most common systemic 
allergic (anaphylactic) reactions are caused by honeybees (Apis mellifera), and certain species of wasps 
in the family Vespidae. Severe generalized immediate-type allergic (anaphylactic) reactions to insect 
stings are of the highest clinical importance. They affect skin, gastrointestinal tract, respiratory and 
cardiovascular system. The classification of severity of anaphylactic reaction following insect stings 
is based on the 4-grade Mueller scale. 
Crucial in patomechanism of anaphylaxis are specific IgE antibodies directed against the compo-
nents of the venom, which mediate the activation of mast cells, the main effector cells of anaphylaxis. 
Therapeutic management in insect venom allergy should be considered in the context of prophylaxis, 
intervention in case symptoms develop, prevention in the form of venom specific immunotherapy (VIT).
There are two steps of VIT 1. Initial dose venom immunotherapy (given according to four protocols 
which differ the time to reach the maintenance dose) 2. Maintenance dose VIT, usually equal 100 g. 
Standard treatment time should span 3–5 years. The main mechanisms of immune tolerance that 
are initiated by VIT are associated with: 1. a decreased reactivity of effector cells, 2. expansion of 
T regulatory lymphocytes with IL-10 expression. Therapeutic effectiveness amounts to 90–100% in 
wasp venom allergy and approximately 80% in bee venom allergy.
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EPIDEMIOLOGY AND NATURAL HISTORY OF VENOM ALLERGY
Methodology of epidemiological studies is based on: 
a) cross-sectional investigational research, 
b) evaluation of in vivo and in vitro tests confirming IgE-mediated venom allergy,
c) retrospective analysis of medical records, including emergency department 
visits, taking into consideration ICD diagnosis codes,
d) combination of the above methods.
In questionnaire-based epidemiological studies, 56.6–94.5% of adult responders 
(depending on climatic conditions) report at least one Hymenoptera sting. The 
incidence of insect venom allergy determined based on positive skin test results 
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and/or positive serum IgE determinations in adult population of individuals who 
do not manifest symptomatic reactions to stings is 9.3–28.7%, while in individuals 
with intense exposure to stings (beekeepers) it amounts to 30–60% [1]. In clinical 
assessment, reactions to stings may appear as local and systemic responses. 
According to European data, the incidence of systemic reactions in the general 
population is 0.3–7.5%, with the value being 0.3–0.8% in children and 14–43% 
in beekeepers [2]. In children, the majority of systemic reactions limited to skin 
only tend to disappear with age. Deaths due to systemic anaphylaxis following 
insect stings are rare (0.03–0.48 deaths per 1 million inhabitants per year) [3, 4]. 
To use an example, in the years 1990–2006, in Germany, 335 deaths were noted 
(an equivalent of 20 deaths per year), where the direct cause was an insect 
(a wasp, bee or hornet) sting. The world literature on the subject does not report 
a single death of a child following Hymenoptera stings. According to studies 
[5, 6] based on a retrospective analysis of medical records, including ICD diagnosis 
codes, and focusing on causes of anaphylaxis in children in Europe, insect 
stings occupy the second place after foods (with peanuts being the predominant 
causative factor), while in adult patients in Australia, Hymenoptera stings are 
the third most common cause of anaphylaxis after foods and medications [7, 8]. 
In Poland, two published epidemiological studies of insect venom allergy 
were carried out in the Lower Silesia region, each of them being a two-stage 
investigation. The first stage consisted of a questionnaire that was completed by 
a patient alone, while the second aimed at data objectivization through completing 
the same questionnaire while assisted by a physician and included a randomly 
selected group of patients who had previously responded positively to questions 
addressing allergic reactions to insect venom. The results of both studies were 
similar — in I part of study prevalence of sting reactions equals 20.7%, including 
large local reaction in 16%, while systemic reactions in 12.9% (according to Mueller 
grade as follows: 8.7% — grade I, 2.5% — grade II, 1.5% — grade III, 0.2% — 
grade IV). Authors reported a high degree of conformity between the prevalence 
of severe systemic reactions to stings as assessed by the patients and verified 
by the physicians, while the indices of prevalence of large local reactions and 
mild systemic reactions as assessed by the patients were overestimated [9, 10]. 
SOURCE OF ALLERGENS
The most common anaphylactic reactions are caused by honeybees (Apis mellifera), 
and certain species of wasps (US — yellow jacket) in the family Vespidae 
(particularly Vespula vulgaris and V. germanica). Anaphylaxis is only occasionally 
caused by other species of Vespidae, such as Dolichovespula spp., hornets (US 
— yellow hornet, Latin — Vespa crabro) and bumblebees (Bombus spp.). The 
highest prevalence of bee venom allergy is noted in people with high exposure to 
stings — beekeepers, their family members, and those living nearby beehives [3]. 
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The European and American nomenclature of particular insect species is diver-
gent [2]. There are basic differences in the morphology of Hymenoptera, 
characteristic properties of their stings and composition of venom. The venomous 
stinger in Hymenoptera evolved from the egg-depositing apparatus. Up to 140 g 
of venom is released per a single bee sting (usually 50 g), and about 3 g per 
a wasp sting. In bee stings, the stinger and venom apparatus remain in the skin 
and continue to release the venom afterward, while wasps can usually retract 
their stingers after stinging. The knowledge on venom composition and the 
structure of its allergens is the basis of appropriate diagnostic management and 
treatment of Hymenoptera venom allergy. In case of bees, venom is collected from 
the venom sac by electrical stimulation developed by Benton [11]. The method of 
obtaining wasp venom from natural sources is more difficult and consists in 
collecting venom sacs from individual insects after anesthetizing the entire nest 
followed by its freezing. After thawing, the stingers are removed from particular 
wasps to isolate venom sacs and extract venom [12]. The technique is employed 
due to safety reasons. Separation of venom components into particular specific 
gravity-dependent fractions is performed using classic chromatography [13]. 
Thanks to such methods, the structure and amino acid sequence of Hymenoptera 
venom components have been understood. Molecular biology methods allow for 
producing recombinant venom analogs (Protein Database, www.allergen.org). The 
systematic nomenclature of purified allergens constituting venom components is 
based on the Linnaean taxonomy abbreviations, while the Arabic numerals denote 
the chronology of their discovery. The procedure is in accordance with the 
recommendations of the Allergen Sub-Committee of the World Health Organization 
and International Union of Immunological Societies [14]. In view of their biological 
role, allergens are divides into major and minor, with the criterion of discrimination 
being the percentage of >50% of allergic individuals who test positive for specific 
IgE antibodies for a given venom component [15]. The most important major 
allergens of honey bee venom are phospholipase A2 (Api m1), a cytotoxic enzyme, 
and hyaluronidase (Api m2), whose amino acid sequence is in 50% identical with 
wasp venom hyaluronidase. Another component, melittin (Api m4), which 
constitutes 50% of bee venom dry mass, is a minor allergen, but it manifests 
a potent cytotoxic activity. The principal components and major allergens of wasp 
venom include phospholipase A1 (Ves v1), hyaluronidase (Ves v2) and antigen 5 
(Ves v5). Additionally, the venom of both Hymenoptera species contain low 
molecular compounds (histamine, catecholamines) and peptides (bee venom — 
apamin, MCD peptide, tertiapin, cardiac peptide, wasp venom — mastoparan, 
kinins) with a locally high cytotoxic potential that may be extended in case of 
multiple stings. The known allergens constituting the components of bee and 
wasp venom are characterized in Table 1 [16].
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T a b l e  1
Overview of the identified Apis melifera and Vespula vulgaris venom allergens [16], modified. 
MW — molecular weight, CRP — carbohydrate-rich protein, DPP IV — dipeptidylpeptidase IV, 
DW — dry weight, MRJP — Major Royal Jelly Protein
Allergen Common name/function MW (kDa)
Potential 
N-glycolisation
% DW
Api m 1 Phospholipase A2   17 1 10–12%
Api m 2 Hyaluronidase   45 2 1–3%
Api m 3 Acid phosphatase   49 2–3 1%
Api m 4 Mellitin     3 0 50
Api m 5 Allergen C/DPP IV 100 5–7 1%
Api m 6
Cysteine-rich  
trypsin inhibitor
    8 0 1–2
Api m 7 CUB serine protease   39 2–4 ?
Api m 8 Carboxyl-esterase   70 4 ?
Api m 9 Serine carboxy-peptidase
Api m 10 Ikarapin-CRP   55 3 ?
Api m 11.0.101 MRJP 8   65  6 ?
Api m 11.01.201 MRJP 9   60 3 ?
Api m 12 Vitellogenin 200 1 ?
Ves V 1 Phospholipase A1   35 0 6–14
Ves v 2a Hyaluronidase   42 2–4
1–3
Ves v 2b Hyaluronidase   42 2
Ves v 3 DPP IV 100 3 1
Ves v 4 CUB protease   42 2–4 ?
Ves v 5 Antigen 5   25 0 5–10
Ves v 6 Vitellogenin 200 4 ?
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SYMPTOMATOLOGY OF INSECT STINGS REACTIONS
Exposure to Hymenoptera insects venom may cause both local and generalized 
reactions, including severe, life-threatening systemic hypersensitivity reactions. 
The phenomenon seems to be associated with several factors: 
1. subcutaneous penetration of the allergen, resulting in its higher concentration 
in situ, 
2. the number, allergic poly-sensitization and physical properties of venom 
allergens, the majority which are low molecular proteins that easily diffuse into 
the circulatory system, 
3. chemical properties of venom components, the majority of which demonstrate 
enzymatic activity against cell membrane phospholipids, thus facilitating local 
toxic activity, 
4. availability of mast cells, which are much more widely represented in the 
skin as compared to other tissues. 
In practice, the highest clinical importance is characteristic of severe generalized 
allergic (anaphylactic) reactions. Their symptoms affect the skin, gastrointestinal 
tract, respiratory and cardiovascular system. The classification of anaphylactic 
reactions following insect stings is based on the 4-grade Mueller scale (Table 2) [2]. 
T a b l e  2
Classification of systemic reaction to insect stings by Mueller [2]
Grade I Generalized urticaria, itching, malaise, and anxiety
Grade II Any of the above plus two or more of the following: angioedema,  
chest constriction, nausea, vomiting, diarrhea, abdominal pain, dizziness
Grade III Any of the above plus two or more of the following: dyspnea, wheezing, stridor, 
dysarthria, hoarseness, weakness, confusion, feeling of impending disaster
Grade IV Any of the above plus two or more of the following: fall in blood pressure,  
collapse, loss of consciousness, incontinence, cyanosis
While assessing neurological symptoms understood as altered levels of consciousness, 
the Glasgow scale is employed. Various authors emphasize the possibility of the 
patient developing Kounis syndrome or in other words acute coronary syndrome 
as the effect of mediators (histamine, leukotriene C4, prostaglandin D2) released 
from the coronary arteries mast cells in adults and children [17, 18]. Of lesser 
importance are symptoms other than anaphylactic, the symptomatology of which 
is presented in Table 3 [19].
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T a b l e  3
Symptomatology of other than anaphylaxis reactions to insect stings [19]
Type of reaction Symptomatology
Local toxic reaction (normal) Area of pain, redness and swelling <10 cm in diameter, 
lasting <24 hours and resolving spontaneously.
Large local reaction Swelling >10 cm in diameter which persists for >24 hours. 
Even in case of very LLR’s, they are treated as mild allergic 
reactions. May induce non-infectious lymphangitis. Only very 
rarely LLR’s situated near the airways do cause clinically sig-
nificant airway obstruction.
Unusual reaction Occurs within few hours to few days after the sting. Usually: 
1. neurological symptoms of unknown origin: Guillain-Barré 
syndrome, neuritis, epilepsy, psychosis. 2. others: nephrotic 
syndrome, Schönlein-Henoch purpura, serum sickness. May 
accompany local or systemic allergic reactions. 
Systemic toxic reaction Occurs after multiple stings. May be fatal. In children, a fatal 
dose is equal to 500 bee stings [2]. A high dose of venom toxins 
causes multiple organ failure. Typical symptoms: weakness, 
vomitus, diarrhea, wheezing, pulmonary edema. Psychosis, vi-
sual impairment, hemolysis, rhabdomyolysis, thrombocytope-
nia and hemoglobinuria with renal failure may be present.
PATHOMECHANISM OF HYMENOPTERA VENOM ANAPHYLAXIS
With respect to its pathogenesis, Hymenoptera-allergens anaphylaxis is a typical 
immediate-type allergic reaction. Specific IgE antibodies directed against the 
components of the venom mediate the activation of mast cells and basophils, 
effector cells of anaphylaxis, leading to the release of mediators that cause the 
acute manifestation of the disease. In the greatest majority of cases, a single sting 
is causative for the reaction. The acute reaction usually develops 10–30 minutes 
after the sting, although the latency might be shorter or longer. Dual reactions 
within a few hours may also occur. 
Mast cells, the principal effector cells of anaphylaxis, differentiate from 
pluripotential CD34+ stem cells and their precursors demonstrate the ability 
to circulate with blood and home to all tissues except the brain tissue. The 
richest representation of mast cells is found in the skin and mucosa and 
submucosa of the respiratory and gastrointestinal systems. Based on different 
staining of intracellular granules, one can distinguish the population of MCT 
mast cells that contain tryptase only and MCTC, which contain — in addition to 
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tryptase — also another neutral serine protease — chymase, carboxypeptidase 
(a zinc-dependent metalloprotease) and G cathepsin. The division is concurrent 
with the functional differentiation of the homed stem cells into two groups: T 
lymphocyte-dependent mast cells (only tryptase is present in the cytoplasmic 
granules and among metabolites of arachidonic acid derivatives, C4 leukotriene 
predominates over D2 prostaglandin) and non-lymphocyte T-dependent mast cells 
(all proteases typical for mastocytes are represented in the granules and among 
metabolites of eicosanoids, D2 prostaglandin predominates over C4 leukotriene) 
[20, 21]. As a result of the IgE-dependent reaction, mediators are released from 
the granules (where they are stored in an active form) or synthesized de novo 
(from cell membrane phospholipids), similarly as cytokines, chemokines and 
growth factors. Preformed and synthesized de novo mediators play a crucial role 
in anaphylaxis and determine clinical symptoms of the early (usually occurring 
within 5–30 minutes) phase of the allergic reaction, such as swelling, increased 
vascular permeability and bronchial spasm. Cytokines, chemokines and growth 
factors determine the clinical presentation of the late phase (generally developing 
within 2–6 h) that is associated with chronic inflammation; they are of a lesser 
importance in anaphylaxis. Clinical symptoms evoked by the activity of mastocyte 
mediators mostly affect the organs where the pool of the homing mast cells is 
large. In diseases occurring with excessive proliferation of mast cells and an 
increase of their pool in the body (the so-called clonal mast cell disorders, such 
as mastocytosis), due to a large load of the released mediators, the anaphylactic 
reaction may be particularly violent and life-threatening.
Since 1987, tryptase has been recognized as a biomarker of the anaphylactic 
reaction to insect venom and mastocytosis, as mast cells constitute its practically 
only important source [22] — the tryptase content in mastocytes is 100–1000 
times higher as compared to basophils, while the mediator is absent in the 
remaining cells. Human tryptase occurs in two forms — as non-active pro-- 
and pro--tryptase and active, mature -tryptase. The available methods of 
determining tryptase concentrations allow for detecting both the pro-form and 
the mature form. The majority of tryptase determined in body fluids of healthy 
individuals represents the constitutive, ever-present pro--tryptase and pro--
tryptase, which are a marker of the entire mastocyte pool in the body that is 
useful in assessing clonal mastocyte disorders. On the other hand, concentrations 
levels of mature -tryptase stored in mast cell granules increase in the course 
of anaphylaxis in consequence of mast cell degranulation, constituting a marker 
of their activation also post mortem [23]. Genes encoding both forms of tryptase 
and their location in humans are known:  tryptase — TPSA1 gene (16p13.3), 
 tryptase — TPSAB1 gene (16p13.3) [24]. Attempts have been also made to use 
PAF and PGD2 metabolites in studies on anaphylaxis as the main prostanoid 
that is released from mast cells in the course of IgE-dependent activation [25–28].
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DIAGNOSIS OF HYMENOPTERA VENOM ALLERGY
Diagnostic management of Hymenoptera venom allergy is employed solely in 
patients with a history of the generalized anaphylactic reaction. Its objectives 
are to: 
1. verify the reaction grade and objectivize the symptoms, 
2. identify the species of the insect that triggered the symptoms, 
3. determine the pathomechanism of the reaction, 
4. define additional risk factors. 
The first objective is achieved based on taking the medical history of the patient 
and analyzing medical records pertaining to the post-sting reaction. Identification 
of the insect and determination of the pathomechanism are implemented through 
studies in vivo and/or in vitro, which aim at demonstrating specific IgE to bee 
and wasp venom by skin testing and serum-specific IgE. Optimally, the diagnostic 
management should be performed twice: within several days following the sting 
and after 3–6 weeks after the systemic reaction [29, 30]. In practice, testing is 
more commonly done once and then the recommended timing is within 3–6 weeks 
following the sting. Testing is performed using skin pricks with the concentration 
range of 0.01–100 μg/ml. If the results of the above tests are negative, intradermal 
tests must absolutely be performed (0.02 ml volume of venom allergen solution 
with increasing concentration values from 0.001 to 1.0 μg/ml) [2, 31]. In view 
of their higher sensitivity, in some centers only intradermal tests are done, as 
they are believed to be decisive (the gold standard) in allergy to insect venom. 
Determinations of serum specific IgE should be performed employing the most 
sensitive methods, such as UniCAP or Immulite 2000, which are characterized 
by zero concentration detectability and their results, are expressed on a 6-grade 
scale [32]. In some patients who test positive both for wasp and bee venom, it is 
necessary to determine whether double positivity is caused by true sensitization to 
allergens characteristic of both Hymenoptera species. In the majority of patients, 
positivity for components of both venoms result from a cross-reaction to common 
carbohydrate determinants (CCD), which belong to plant and food panallergens. 
A considerable progress in diagnostic management of double sensitization has 
been achieved owing to recombinant allergens of major rApi m1, rVes V1 and 
rVes V5 [16, 33, 34]. The method for determining recombinant major allergens 
(ImmunoCAP, Phadia) is also available in Poland.
Non-standard diagnostic management of insect venom allergy that is offered 
only by a few centers is the basophil activation test (BAT) with flow-cytometric 
determination of the expression of the activation markers (CD63 and CD203) 
[35–37]. Reports have been published on a potential effectiveness of the test in 
the diagnostic management of reactions with negative results of venom specific 
IgE [38], as well as in monitoring insect venom immunotherapy [39–41] and 
in patients with mastocytosis [42, 43]. If the medical history of the patient 
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indicates severe life-threatening anaphylaxis following the insect sting, concomitant 
risk factors should be determined. To achieve this goal, the baseline tryptase 
(bsT) concentration should be determined as the marker of mastocyte pool in 
the body. Concentration values <10 μg/l are regarded normal. Concentration 
levels >11.4 μg/l indicate clonal mast cell disorders and considerably increase 
the risk of the patient developing life-threatening symptoms following the sting 
[44]. Concentration levels >20 μg/l are included among the diagnostic criteria of 
systemic mastocytosis [45]. In view of possible mastocytosis without concomitant 
skin lesions, in patients after life-threatening post-sting reactions, there is all the 
more reason for bsT determination [46]. Despite the fact that clonal mast cell 
disorders are a particularly rare disease entity in children, clinical assessment of 
the skin should always take into consideration urticaria pigmentosa [47]. Elevated 
bsT in children with severe urticaria pigmentosa-type lesions is a predictor of 
anaphylaxis severity after insect stings [48]. Risk factors for anaphylaxis due to 
Hymenoptera venom are presented in Table 4 [19]. The increasing role of bsT 
assessment in insect venom allergy is supported by studies of large cohorts 
of patients that indicate its usefulness both in diagnostic management and 
immunotherapy monitoring in these patients [28, 49–53].
T a b l e  4
Risk factors for anaphylaxis due to Hymenoptera venom [19]
Risk of frequent  
exposure
— Beekeepers, their families and neighbors
— Other professions, including: fruit and baked foods sellers 
 foresters, gardeners, firefighters, farmers, construction 
 workers, truck drivers
— Intense outdoor activity
Elevated risk of severe 
anaphylaxis
— Prior epidode(s) of severe sting anaphylaxis (grade III and IV)
— Age >40 
— Cardiovascular disease
— Asthma
— Physical and mental stress
— Certain drugs: -blockers (including eye drops), ACE inhibitors
— bsT conc. >11.4 μg/l (mastocytosis is not rare in such cases)
— Cutaneous (urticaria pigmentosa) or systemic mastocytosis
Another issue is securing blood for tryptase determinations in the course of 
an acute anaphylaxis episode. In such circumstances, blood should be collected 
within 15 minutes to 3 hours following the onset of symptoms. The procedure 
of material preparation is not difficult; optimally, the <5 ml volume (in children 
— 0.5 ml) of blood collected to a clot tube should be centrifuged and stored at 
–20oC. Tryptase is stable; 50% of tryptase is determinable even after 4-day storing 
at room temperature [54]. Determinations of tryptase concentration are performed 
using ImmunoCAP Tryptase (Phadia).
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FUNDAMENTALS OF THERAPEUTIC MANAGEMENT 
OF HYMENOPTERA VENOM ALLERGY
Therapeutic management should be considered in the context of the following:
1. prophylaxis through avoiding contact with the triggering factor, 
2. intervention in case symptoms develop, 
3. prevention in the form of venom specific immunotherapy [55].
Regardless different health service organization in European countries, 
following the guidelines both in diagnostic and treatment procedures is crucial 
with reference to patient’s safety, and doctor’s law’s consequences [56]. 
In the interventional management of the patient manifesting anaphylaxis 
symptoms, promptness of intervention is of fundamental importance. In case 
of fully symptomatic anaphylaxis, adrenaline is a life-saving agent. Here, when 
given in standard doses, advantage is taken of its effect on adrenergic receptors: 
1 (decreased vascular leakage, increased peripheral resistance, decreased 
mucosal edema), 2 (inhibition of insulin and noradrenalin release), 1 (positive 
chronotropic and inotropic effects) and 2 (bronchodilation, intensification of 
glycogenolysis, inhibition of release of inflammatory mediators) [57]. There are 
no absolute contraindications for adrenaline administration. In the course of 
initial intervention during anaphylaxis, oxygen is to be promptly administered, 
vigorous fluid resuscitation should be commenced, help should be called for and 
the principle of laying the patient flat with elevated lower extremities needs to 
be observed, what protects the affected individual from death in the mechanism 
of superior vena cava syndrome and empty ventricle syndrome. It should be 
remembered that medications other than adrenaline (antihistamines and systemic 
glucocorticosteroids; in patients with asthma and bronchial obturation — 
additionally rapid acting inhaled 2-mimetics) are only adjuvant treatment in 
anaphylaxis. Lack of well-documented case-control studies on treatment of patients 
undergoing anaphylactic reactions is emphasized, with the exception of reports 
addressing insect venom immunotherapy [58, 59]. More advanced intervention 
management in the course of anaphylaxis is a subject of separate reports [60–63]. 
In view of the importance of the problem, consensuses on management principles 
in anaphylaxis are constantly updated [64] and their implementation in everyday 
practice improves the quality of interventions employed [65]. 
The history of subcutaneous insect venom immunotherapy spans approximately 
50 years. In the initial phase, insect whole body extract therapy was employed. 
With time, the method was proven to be of low effectiveness and the allergen 
dose of low reproducibility and this is why at present, while providing therapeutic 
management with initial and maintenance doses, water solutions of venom extract 
are employed, while in maintenance therapy there is an additional possibility of 
using depot preparations. Investigations on common availability of recombinant 
allergen preparations are increasingly more advanced; such preparations are 
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individually selected to match the sensitization profile of the patient (component 
resolved diagnosis — CRD) [66, 67].
Specific venom immunotherapy (venom immunotherapy — VIT) is the treatment 
of choice in patients (both adult and pediatric above 5 years of age, in keeping 
with the current recommendations though in severe cases lower age limit is 
flexible) in cases when both the below given criteria are met [2]:
1. severe generalized reaction in past medical history with respiratory symptoms 
(grade III according to H.L. Mueller) and/or circulatory symptoms (grade IV according 
to H.L. Mueller),
2. IgE-dependent allergy to a given Hymenoptera species.
In case of generalized systemic non-life threatening reactions (systemic 
reactions grade I and II according to H.L. Mueller), the decision to employ 
venom immunotherapy may be affected by other factors, such as high exposure 
(occupational, family members of beekeepers, individuals dwelling close to 
apiaries), concomitant cardiovascular diseases, mastocytosis, mental factors 
(e.g. profoundly deteriorated quality of life due to fear of insect stings that 
renders normal daily functioning impossible). In patients with confirmed double 
sensitization VIT with extracts of both wasp and bee venom is indicated. Its 
therapeutic effectiveness is high, amounting — depending on the type of allergy 
— to 90–100% in wasp venom allergy and approximately 80% in case of allergy 
to bee venom [2]. In comparative studies performed in cohorts of desensitized 
vs. non-desensitized patients, a significant decrease of risk of severe systemic 
reactions has been observed in desensitized individuals [68, 69]. The recently 
emphasized new advantage of VIT is the improvement of quality of life of the 
patients, both in adults and children [70–73]. The criteria of qualifying patients 
for VIT according to EAACI are presented in Table 5 [1]. 
T a b l e  5
Indication for venom immunotherapy according to EAACI guidelines [79]
Type reaction 
adults/children
Diagnostic tests 
(skin tests  
and/or IgE)
Decision regarding 
venom  
immunotherapy
Respiratory and/or cardiovascular  
symptoms — IIIo/IVo in Mueller’s grade
Positive
Negative
Yes
No
Urticaria/oedema — Io/IIo if risk factors  
or QoL impairment present
Positive
Negative
Yes
No
Large local Positive or negative No
Unusual reaction Positive or negative No
VIT is also not taken into consideration in individuals, in whom IgE specific 
to wasp or bee venom has been detected accidentally and their medical history 
54
is negative for sting-following reactions. Similarly, VIT is not recommended in 
patients with toxic reactions, atypical or extensive local reactions, although in 
the United States, there have been published pilot studies on selected cases 
of desensitization of patients with extensive local reactions [74]. Sublingual 
administration of venom specific immunotherapy in patients with extensive local 
reactions, although presented in case reports, is not recommended [75, 76].
The protocols of initial immunotherapy that allows for achieving the maintenance 
dose may be characterized as follows:
1. accelerated (several hours up to several days); the in-hospital treatment is 
provided using the ultra-rush or rush method, 
2. conventional or cluster, when the treatment is provided over a prolonged 
period (from several to ten-odd weeks). 
Reports based on randomization of patients to three desensitization protocols 
employing the initial dose indicate a significantly lower prevalence of adverse 
symptoms, both local and systemic, in patients treated according to the ultra-
rush protocol as compared to the rush or conventional protocol [77]. 
With the standard maintenance dose of 100 μg/ml, what corresponds to 
approximately two bee stings and as many as several score wasp stings, the 
maintenance phase of the therapy should span 3–5 years. In justified cases, e.g. 
in patients with clonal mastocyte disorders or in individuals undergoing desensiti-
zation who continue to manifest systemic reactions after field stings, what indicates 
lack of appropriate immune protection, the maintenance dose of the venom 
extract may be gradually increased up to 200 μg, with the treatment protocol 
starting anew. In the first year of therapy, the interval between administrations 
of subsequent maintenance doses is four weeks, in case of 2–5-year therapy — 
six weeks, and in cases of depot extract given as a maintenance dose, the 
planned interval between the doses is increased to eight weeks. In view of the 
minimized, but still apparent risk of the patient developing a systemic reaction, 
each individual with the past history of anaphylactic shock, in spite of the 
immunotherapy, should be equipped with an anaphylactic kit and always have 
it on his person. In Polish centers of internal medicine, the most commonly 
employed protocol of management with the initial dose is the rush protocol, and 
in pediatric centers — ex aequo the conventional and ultra-rush protocols [78]. 
It is estimated that at present, approximately 200 children and several hundred 
adults are undergoing treatment. 
Contraindications to venom specific immunotherapy in patients allergic to 
Hymenoptera venom do not differ from the generally accepted contraindications 
pertaining to immunotherapy for other allergens. They include lack of the patient’s 
cooperation, age below 5 years of life (in case of life-threatening reactions, the 
criterion is not restrictive in character), active neoplastic or autoimmune diseases, 
severe decompensated generalized diseases, chronic organ failure, pregnancy 
(preliminary immunotherapy) and other situations where the benefit/risk ratio 
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is not advantageous for the patient. Administration of -receptor blockers and 
angiotensin converting enzyme (ACE) inhibitors is recognized as an additional 
risk factor of the patient developing systemic adverse effects, especially during 
the phase of employing increasing immunotherapy doses [2, 79]. 
The fundamental objective of venom specific immunotherapy is to produce 
induced tolerance in peripheral T lymphocytes to sensitizing allergens. Once 
the immune tolerance is achieved, T regulatory lymphocytes (TREG) start to 
produce great amounts of anti-inflammatory cytokines. The hitherto understood 
mechanisms of immune tolerance that are initiated by specific immunotherapy 
are associated with [80–90]: 
1. a decreased reactivity of antigen-presenting cells (dendritic cells) and 
peripheral effector cells (mastocytes, basophils, eosinophils) following allergen 
stimulation (the effect appears after several days of treatment), 
2. expansion of T regulatory lymphocytes (TREG, CD4+ CD25+ Foxp3+) and 
expression of their cytokine pattern (IL-10); the full effect is observed after several 
months of treatment,
3. suppression of Th1 and Th2 cells, 
4. a regulatory effect on B lymphocyte-dependent synthesis, with limitation of 
specific IgE production and at the same time intensified production of IgG4 and/
or IgA blocking antibodies (the effect is observed after several years of treatment).
Early changes have been recently described, appearing within the few initial 
hours after the sting and associated with an accelerated tryptophan degradation 
in blood polynucleated cells and monocytes, increased IL-10 synthesis and 
increased expression of ILT (immunoglobulin-like transcript) family members [91, 
92]. Nevertheless, not a single laboratory test allows for confirming effective 
immunotherapy. Hence, in immunoprotection monitoring and for possible 
determination of the moment when termination of treatment is warranted, the 
gold standard is sting challenge of the patient by a live insect [93]. It allows for 
identifying these patients, in whom treatment can be safely terminated (in no less 
than 6–18 months following the achievement of maintenance dose). In practice, 
the procedure is employed only in infrequent centers. Sting challenge is not 
recommended as a diagnostic tool in patients not undergoing desensitization as 
it is potentially dangerous. The most recent reports indicate that determining the 
gene expression profile may be a valuable tool in individual patients in estimating 
risk factors of severe insect venom anaphylaxis, also in individuals with latent 
forms of mastocytosis [94–96].
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